Global Therapeutic Vaccines Market

Therapeutic Vaccines Market Size, Share, Growth Analysis, By Product Type(Autoimmune Disease Vaccines, Addiction Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines), By Type(Protein-based Vaccines, DNA Vaccines, Recombinant Vector Vaccines, Conjugate Vaccines), By Application(Cancer, HIV/AIDS Vaccines, Infectious Diseases Vaccines, Allergy Vaccines), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35J2111 | Region: Global | Published Date: May, 2024
Pages: 215 | Tables: 95 | Figures: 78

Therapeutic Vaccines Market News

  • In February 2024, a clinical trial for mRNA-4359 cancer vaccine was launched in the United Kingdom. The trial is sponsored by Moderna, a leading pharmaceutical company and is projected to test the vaccine on patients from around the world over the next three years.
  • In January 2024, Elicio Therapeutics, a clinical-stage biotechnology company based in the United States, revealed its preclinical data regarding how its therapeutic cancer vaccine boosted the efficacy of T cell receptor-modified T-cell (TCR-T) therapy in mice.
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Therapeutic Vaccines Market size was valued at USD 25.7 billion in 2022 and is poised to grow from USD 53.71 billion in 2023 to USD 119.39 billion by 2031, growing at a CAGR of 10.5% in the forecast period (2024-2031).

Therapeutic vaccine manufacturers should invest heavily in R&D of new vaccines that are more effective than what’s currently available in the market. Therapeutic vaccine companies can also collaborate and partner with each other to fast track the development of new vaccines and reduce time-to-market. Mergers and acquisitions are also popular strategies that could help therapeutic vaccine market players maximize their market share and presence. 'Novartis', 'Argos Therapeutics', 'Johnson & Johnson', 'Pfizer', 'Vaccinogen Inc.', 'Affiris', 'Antigenics', 'Bavarian Nordic', 'Biovest International', 'AstraZeneca', 'Merck & Co.', 'Dynavax Technologies Corporation', 'GlaxoSmithKline', 'Sanofi', 'Intellect Neurosciences', 'Agenus Inc.', 'Celldex Therapeutics', 'Cel-Sci', 'Curevac', 'Celtic Pharma', 'CSL Limited', 'Medimmune'

Surge in incidence of infectious and chronic diseases around the world has increased awareness regarding preventive healthcare among people around the world, which in turn, is forecasted to benefit sales of therapeutic vaccines.

Use in Immunotherapy: Therapeutic vaccine vendors can focus on developing new products that can be used in specific immunotherapies to improve the treatment and efficacy rate among cancer patients. Therapeutic vaccine companies can modify immune responses as per tumor and improve the chances of successful immunotherapy.

North America is estimated to account for a substantial share of the therapeutic vaccines market owing to the presence of a developed healthcare ecosystem and high healthcare expenditure. Growing investments in R&D of novel therapeutic vaccines in this region will also aid the dominance of this region in the market. The United States is projected to spearhead the demand for therapeutic vaccine in North America followed by Canada across the forecast period and beyond. An established clinical trial and regulatory approval system in the United States helps therapeutic vaccine market growth.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global Therapeutic Vaccines Market

Report ID: SQMIG35J2111